Premium
Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation
Author(s) -
Irish A. B.,
Simons L. A.,
Savdie E.,
Hayes J. M.,
Simons J.
Publication year - 1992
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1992.tb02119.x
Subject(s) - medicine , lipoprotein(a) , transplantation , lipoprotein , dialysis , kidney disease , nephrosis , continuous ambulatory peritoneal dialysis , apolipoprotein b , peritoneal dialysis , gastroenterology , endocrinology , cholesterol
Abstract: Lipoprotein(a) is an independent risk factor for cardiovascular disease. Lipoprotein(a) levels were measured in 196 patients (103 Male [M]: 93 Female [F]) with chronic renal diseases and in 116 controls. Median levels of Lipoprotein(a) [Lp(a)] were found to be significantly elevated in patients with untreated chronic renal disease (285, 285 mg/L; M, F; range 30–1675 mg/L) and in those treated with continuous ambulatory peritoneal dialysis (320, 603; M, F; range 50–1450) compared with controls (70, 51; M, F; range 1–750; p <0.01 Males, p <0.001 Females). Lp(a) levels in patients treated by haemodialysis (133, 35; M, F; range 5–685) and renal transplantation (100, 95; MJF; range 10–1700) were not significantly different from controls. Lipoprotein(a) levels correlated inversely with serum albumin in the combined dialysis group (r= ‐034, p < 0.001), and with urinary protein loss in the combined transplant and chronic renal diseases groups (r = 0.29, p <0.01). This correlation of Lp(a) with protein metabolism suggests a similarity with changes in other apolipoprotein‐B containing lipoproteins in nephrosis. These findings may be relevant to the increased risk of atherosclerosis in patients with chronic renal disease and to their optimum mode of renal replacement therapy. (Aust NZ J Med 1992; 22:243–248.)